Celecoxib Window of Opportunity Trial to Assess Tumor and Stroma Responses

Summary

The overall purpose of this study is to assess whether celecoxib can reduce the change in collagen alignment and inflammatory response in the tumor tissue of primary breast cancer patients with invasive breast carcinoma after 2 weeks of oral intake.

Timeline

Start

2017-09-20

Primary completion

2018-10-10

Completion

2018-10-10

Outcome

Outcome not reported

Stopped (Enrollment): “Slow accrual”

Drugs

Indications